InVitae Corp (NYSE:NVTA) CFO Shelly D. Guyer Sells 24,447 Shares
InVitae Corp (NYSE:NVTA) CFO Shelly D. Guyer sold 24,447 shares of InVitae stock in a transaction on Monday, August 19th. The stock was sold at an average price of $25.38, for a total value of $620,464.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of InVitae stock traded up $0.69 on Wednesday, reaching $26.45. The company’s stock had a trading volume of 3,174,525 shares, compared to its average volume of 1,863,986. The company has a quick ratio of 7.18, a current ratio of 7.18 and a debt-to-equity ratio of 0.36. InVitae Corp has a 52 week low of $9.04 and a 52 week high of $28.75. The company has a market capitalization of $2.40 billion, a price-to-earnings ratio of -13.63 and a beta of 2.53. The firm’s fifty day simple moving average is $24.83 and its two-hundred day simple moving average is $21.71.
InVitae (NYSE:NVTA) last issued its quarterly earnings data on Tuesday, August 6th. The medical research company reported ($0.54) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.06). InVitae had a negative return on equity of 58.48% and a negative net margin of 83.69%. The firm had revenue of $53.48 million during the quarter, compared to the consensus estimate of $50.17 million. During the same period in the previous year, the firm earned ($0.47) EPS. The business’s revenue was up 43.3% on a year-over-year basis. As a group, research analysts predict that InVitae Corp will post -2.11 EPS for the current year.
A number of analysts have commented on NVTA shares. Chardan Capital reissued a “buy” rating and issued a $30.00 target price on shares of InVitae in a report on Tuesday, June 11th. Benchmark reissued a “buy” rating and issued a $28.00 target price (up previously from $26.00) on shares of InVitae in a report on Wednesday, August 7th. Oppenheimer set a $34.00 target price on InVitae and gave the stock a “buy” rating in a report on Wednesday, August 7th. Zacks Investment Research lowered InVitae from a “buy” rating to a “hold” rating in a report on Friday, April 26th. Finally, Leerink Swann set a $31.00 target price on InVitae and gave the stock a “buy” rating in a report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $28.17.
InVitae Company Profile
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders.
Read More: Average Daily Trade Volume Explained
Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.